<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Coltrera, Francesca</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Park, Seung-Jung</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">BEST Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-04-24 09:14:01</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Percutaneous coronary intervention with second-generation everolimus-eluting stents was inferior to coronary artery bypass graft surgery in patients with multivessel coronary artery disease in the open-label prospective randomized BEST trial. The composite primary outcome (all-cause death, myocardial infarction, target vessel revascularization) occurred more frequently in patients randomized to percutaneous coronary intervention.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>